The hunt for biomarkers for patients with hepatocellular carcinoma (HCC) or liver cancer ensues as an explosion of novel agents, either approved or in the clinical trials pipeline, opens the door for tremendous opportunity to develop heretofore not possible treatments...
Liver Cancer
Category
Can-Fite Biopharma Completes End-of-Phase 2 with FDA; Agreement Reached on Phase 3 Trial Design to Support NDA Submission
Can-Fite Pharma announced the successful completion of an End-of-Phase 2 meeting with the U.S. FDA regarding its recently completed Phase II study of namodenoson in the treatment of hepatocellular cancer (HCC). The purpose of the meeting was to review the Phase II...
Michigan State University Investigator Receives $2.1m to Study Existing Treatments for Select Rare Diseases
Michigan State University (MSU) College of Medicine investigator Bin Chen just was awarded $2.1 million by the National Institutes of Health (NIH) to scour vast databases of existing drugs in a quest to treat orphan diseases. The investigative team received an...
Shanghai’s Zhongshan Hospital Researchers Find Certain Chinese Herbal Medicines Causing Liver Cancer
A research team from Shanghai’s Zhongshan Hospital joined by two Shanghai institutes under the Chinese Academy of Sciences have discovered that one-third of liver cancer samples features a mutation caused by aristolochic acids and connect this to the clinical use of...
Navy Military Medical University of Shanghai Study Reveals Better Survival with Neoadjuvant Radiotherapy vs. Surgery Alone for HCC
Chinese researchers from Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai showed that neoadjuvant 3D conformal radiotherapy provided significantly better post-surgery survival outcomes than surgery alone in patients with resectable...
City of Hope First Research Site to Test ET140202 on Liver Cancer Patients
City of Hope reports that it is the first institution in the United States to open an immunotherapy clinical trial for liver cancer that, if successful, eventually represents a transformative treatment of the often fatal disease into an outpatient procedure. The...
Retrospective Study of Sorafenib Efficacy and Safety in Chinese Patients with Recurrence Rate of Post-Hepatic Carcinectomy
Chinese investigators conducted a retrospective analysis of sorafenib efficacy and safety in Chinese patients with a high recurrence rate of post-hepatic carcinectomy. The research team found that sorafenib may be considered as a feasible option in the treatment of...
Bristol-Myers Squibb’s Phase 3 CheckMate-459 Trial Fails to Meet Endpoints in Front-Line Liver Cancer
Bristol-Myers Squibb announced topline results from CheckMate -459, a Phase 3 study evaluating Opdivo (nivolumab) versus Bayer’s Nexavar (sorafenib) as a first-line treatment in patients with unresectable hepatocellular carcinoma (HCC). The trial did not achieve...
UCLA Medical Center Leading Trial to Assess High-Dose MRI-Guided Radiation Therapy for Pancreatic Cancer
Healio reports researchers are launching a multi-institutional trial to test the effectiveness of precise, high-dose, MRI-guided radiation therapy to treat pancreatic cancer. The trial is being led by UCLA Medical Center as well as the Henry Ford Cancer Institute....
CHILTERN: European Program to Improve Outcome of Children with Liver Cancer
The Children’s Liver Tumour European Research Network (ChiLTERN) is an ambitious five-year project that will define effective healthcare interventions in children’s liver cancer, increase our knowledge of the biology of the disease and improve surgical outcomes. It is...
AstraZeneca & AVEO Oncology Form Collaboration to Investigate Liver Cancer Immunotherapy
Richard Staines of PharmaPhorum reports that global commercial sponsor AstraZeneca and AVEO Oncology have formed a partnership to develop cancer immunotherapy combination for liver cancer. AstraZeneca is looking to combine Imfinzi, an anti PD-L1 class drug with...